Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Pathologically diagnosed glioblastoma multiforme or other malignant glioma
• * Recurrent disease
• Must have received prior temozolomide
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 60-100%
• Granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• SGOT ≤ 2.5 times upper limit of normal (ULN)
• Creatinine ≤ 2 times ULN
• Bilirubin ≤ 2 times ULN
• No other active malignancy except for cervical carcinoma in situ or basal cell carcinoma of the skin
• No serious medical or psychiatric illness that, in the opinion of the investigator, would preclude study treatment
• No medical condition that precludes swallowing pills
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from all prior therapy